Introduction
In industrialized countries, endometrial cancer (EC) represents the most common malignancy of the female reproductive tract. The precursor lesion for endometrioid adenocarcinoma of the endometrium, which comprises the majority of ECs, is endometrial hyperplasia (EH). EH is a noninvasive, abnormal proliferation of the endometrial lining of the uterus and associated with a significant risk of concurrent EC or progression to EC. The leading symptoms of EH are bleeding disorders in premenopausal women and vaginal bleeding in postmenopausal women. The most important risk factor is chronic exposure to unopposed estrogen. This narrative review aims to give an overview of the classification, risk factors, and management of EH. We searched the following databases: PubMed and Cochrane Controlled Trials register. We performed the final search in March 2021. Additionally, we performed a systematic literature search of the databases PubMed and Cochrane Controlled Trials register for studies analyzing the efficacy of progestin treatment in women with EH.
Classification of EH and risk of progression to EC
Histologically, EH describes the abnormal proliferation of endometrial glands with a greater gland-to-stroma-ratio than healthy proliferative endometrium but without endometrial stromal invasion. Diagnosis should be based upon histological assessment of a tissue sample obtained by endometrial biopsy, curettage, or hysterectomy. The most widely used classification system for EH is the 2014 World Health Organization (WHO) Classification System which differentiates between:
-
EH without atypia (benign EH) and
-
atypical EH/endometrial intraepithelial neoplasia (EIN).
Anzeige
This distinction is particularly important because clinical management of the two conditions is different, depending on the presence or absence of nuclear atypia. Nuclear atypia is defined as nuclear enlargement with or without prominent nucleoli [1]. EH without atypia constitutes a benign lesion without significant somatic genetic changes caused by extensive exposure to estrogen that is not counterbalanced by the protective effects of progestins. If physiological progesterone levels are resumed or if therapeutic progestins are used, the hyperplastic changes regress and the endometrium becomes healthy again in the majority of cases [2]. EH without atypia seems to rarely progress to EC although evidence supporting this statement is poor. For example, in a case series published in 1985, benign EH only progressed to EC in two (1.6%) out of 122 patients. The first patient with simple hyperplasia developed atypical EH and subsequently EC 11 years after the first diagnosis of EH. The second patient had complex EH which progressed to EC 8.3 years after the initial diagnosis. Neither patient had received progestin treatment or died of their disease [3].
In a case–control study nested in a cohort of 7,947 women diagnosed with EH from 1970 to 2002, 138 women were diagnosed with EC, on average 6 years after the initial diagnosis of EH [4, 13]. The cumulative 20-year progression risk was less than 5% for EH without atypia but 28% for atypical EH. Specifically, for EH without atypia, the cumulative progression risk increased from 1.2% (95% CI, 0.6% to 1.9%) to 1.9% within 4 years (95% CI, 1.2% to 2.6%), to 4.6% within 9 years (95% CI, 3.3% to 5.8%) and up to 19 years after EH diagnosis. For women with atypical EH, the cumulative risk increased from 8.2% (95% CI, 1.3% to 14.6%) to 12.4% within 4 years (95% CI, 3.0% to 20.8%), to 27.5% within 9 years (95% CI, 8.6% to 42.5%) and up to 19 years after the diagnosis of EIN.
Atypical EH has many similarities with endometrioid EC at the molecular level [4]. Concurrent EC was found in 37% of women with atypical EH in a retrospective case series including 219 patients with EIN combined with a review of 31 published studies including a total of 2571 patients [5]. Other studies have documented a risk of concomitant EC in up to 50% of patients with atypical EH [6‐9]. A high risk of concomitant EC among women with atypical EH is also consistent with the high risk of progression to EC observed among women with EH undergoing progestin treatment. This risk of progression to EC has been described to be between 15 and 28% [10‐12]. For example, a retrospective cohort study investigated 242 women with atypical EH, of whom 74% received progestin therapy [12]. The rate of progression to EC was significantly higher without progestin treatment (101.4 versus 20.5 per 1000 woman-years). During a median follow-up of five years, 15% of all women with atypical EH developed EC. The risk for development of EC in women with atypical EH has been shown to be diminished approximately threefold to fivefold when treated with progestin [12]. Another important issue to be considered when assessing the concurrent or future risk of EC among women with atypical EH is the fact that it may be difficult to histopathologically distinguish EIN from EC. Illustrating these diagnostic difficulties, Trimble et al. found over- or underdiagnosis in almost every third specimen [13]. Specifically, independent gynecologic pathologists reviewed 289 endometrial biopsy specimens from women with a community diagnosis of atypical EH and found that in 25% the diagnosis was less severe than atypical EH, whereas in 29.1% EC was already present. This suggests a significant overlap between the different diagnoses of EH without atypia, atypical EH, and EC both in clinical practice as well as in the literature. Therefore, it is reasonable to treat atypical EH as the equivalent of early EC when counseling affected patients.
Risk factors of EH
As its precursor lesion, the risk factors for developing EH are closely related to the well-known risk factors for endometrioid adenocarcinoma of the endometrium. The most important risk factor for both EH and EC is a chronic imbalance of estrogen and progestin in favor of estrogen [14‐18]. Exposure to excessive estrogen without the protective effect of progestin can be endogenous or exogenous in nature. Other risk factors include genetic factors such as hereditary nonpolyposis colorectal cancer (HNPCC, or Lynch syndrome) and Cowden syndrome, which is rare and in most cases related to a mutation in the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) gene, located on chromosome 10q23.31 [19‐22].
Anzeige
Endogenous estrogen exposure
Examples of excessive endogenous exposure to estrogen include obesity, chronic anovulation, early menarche, and late menopause as well as the presence of estrogen-secreting tumors. In obese women, a high amount of adipose tissue is closely associated with higher local and circulating levels of estradiol. This can be explained through various mechanisms. Firstly, an increase in adrenal secretory activity is often observed, which leads to an increase in androgen precursors. These precursors may then be converted to estradiol in peripheral tissues. Secondly, the conversion rate of androstenedione to estrone by the enzyme aromatase rises as this conversion primarily takes place in adipose tissue. Lastly, higher concentrations of estradiol can be found in obese patients as plasma levels of estradiol-binding sex hormone-binding globulin (SHBG) are typically depressed in this patient population [23]. These pathophysiological observations are consistent with clinical findings. For example, in a retrospective cohort study including 916 premenopausal women with abnormal uterine bleeding, patients with a body mass index of over 30 kg/m2 developed complex hyperplasia or EC 4 times more often than lean women (95% CI, 1.36–11.74) [24].
Chronic anovulation is another important risk factor for EH. When anovulation occurs, sex hormone production is not cyclical as in regularly ovulating premenopausal women. Without ovulation, estrogen levels still dominate without the opposing effect of progesterone produced by the corpus luteum after ovulation. This imbalance leads to a continued proliferation of the endometrium resulting in a higher risk of developing EH and eventually endometrioid EC. Common settings associated with anovulation include polycystic ovary syndrome (PCOS), hyperprolactinemia, and perimenopausal hormonal status. In 2009, a meta-analysis of four case–control studies including a total of 4056 women showed an almost threefold risk of developing EC for women with PCOS compared to the general population (OR 2.70, 95% CI, 1.00–7.29) [25]. In 2012, a subsequent meta-analysis of the same studies including another cross-sectional study, confirmed this risk elevation in PCOS patients (OR 2.89, 95% CI, 1.52–5.48) [26]. However, these results need to be interpreted with caution since other authors suspected that the risk increase was exaggerated due to risk factors commonly associated with PCOS such as obesity and diabetes and skewing of the risk estimates due to a potential selection bias in some of the studies [27, 28].
Hormone-secreting tumors can cause an endogenous sex hormone imbalance. For example, granulosa cell tumors represent potentially estrogen-secreting tumors of the ovary. Consequently, EH is diagnosed in 25% to 50% of women with granulosa cell tumors of the ovary [29, 30]. If EH is diagnosed in a patient without other known risk factors, estrogen-secreting tumors should therefore be excluded.
Exogenous estrogen exposure
Estrogen therapy should always be supplemented with a progestin in women with an intact uterus. Unopposed estrogen therapy in women with an intact uterus increases the risk of developing EH and then EC in both premenopausal and in postmenopausal women. This is well illustrated in a meta-analysis including 45 randomized studies of hormone replacement therapy over a minimum period of 12 months in postmenopausal patients [31]. The authors documented a significantly increased risk of EH when women were treated with estrogen alone. The risk increased after 12 months of unopposed treatment with moderate or high-dose estrogen therapy (OR 8.4 and 10.7, respectively) and after 18 to 24 months of treatment with low-dose estrogen therapy (OR 2.4). Other studies have assessed the risk of developing EC in women treated with unopposed estrogens and found a 1.5- to tenfold relative risk increase [32‐36].
Tamoxifen, which is one of the most important agents for endocrine treatment of hormone receptor-positive breast cancer, has been associated with an increased risk for developing EH and EC [37]. Several small studies concluded that tamoxifen-related ECs are mostly diagnosed at an early stage with an overall good prognosis [38‐40]. In contrast, a nationwide case–control study conducted in the Netherlands including 309 patients with a diagnosis of EC after a history of breast cancer and 860 patients with a history of breast cancer but without EC reported a worse prognosis in long-term tamoxifen users due to a higher risk of EC with a higher tumor stage and a less favorable histology [41]. In this study, a longer duration of tamoxifen treatment was associated with a significantly increased risk of EC. The relative risks were 2.0 (1.2–3.2) for 2 to 5 years of tamoxifen and 6.9 (2.4–19.4) for at least 5 years of tamoxifen compared to no tamoxifen therapy. In addition, long-term use of tamoxifen (≥ 2 years) was associated with more stage III and IV ECs compared with non-users (17.4% and 5.4%, respectively, p < 0.01). However, in patients with hormone receptor positive breast cancer the benefits of endocrine therapy with tamoxifen clearly predominate in comparison with the increased risk of EC [41, 42]. A prophylactic use of tamoxifen in healthy patients, on the other hand, should be discussed critically in view of the available data. Two studies suggest that the elevated risk of EH and EC in tamoxifen users might be limited to postmenopausal women. In one of these studies, no significant difference in the development of endometrial abnormalities was observed in premenopausal patients treated with tamoxifen compared to women who received placebo. In contrast, the risk ratio among postmenopausal women was 4.01 (95% CI, 1.70 – 10.90) [43]. Another study found significantly more endometrial abnormalities in postmenopausal women treated with tamoxifen, while no differences in endometrial thickness, uterine volume, or histopathological results were reported in premenopausal patients treated with tamoxifen compared with controls [44]. This clinical aspect is important since tamoxifen can be replaced by aromatase inhibitors in postmenopausal breast cancer patients but still represents the standard of care for premenopausal breast cancer patients.
Lynch syndrome
HNPCC or Lynch syndrome is a genetic disorder inherited in an autosomal dominant fashion. Due to mutations in DNA mismatch-repair (MMR) genes like MSH2, MLH1, MSH6 and PMS2 leading to microsatellite instability (MSI) patients with HNPCC have a lifetime risk of 40–60% for development of EC [45]. In a recent prospective cross-sectional study conducted in the United Kingdom 500 women with atypical EH or EC were tested for Lynch-Syndrome. In total, 16/500 participants had Lynch-Syndrome (3.2%, 95% CI 1.8% to 5.1%) and 11 more (2.5%) were tested positive for MMR variants of uncertain significance. The proportion of affected patients with Lynch-Syndrome (3.2%) in this study population was similar to colorectal cancer. Thus, the authors suggest unselected screening of atypical EH and EC for MSI [46]. EC is also diagnosed at a younger age in women with Lynch-Syndrome [47]. In a study including 69 women with Lynch-Syndrome-associated EC, 18% were diagnosed under 40 years, compared with a mean age of 60 years in women without Lynch-Syndrome [48]. Molecular alterations like MSI seem to take place early in the degenerative process. Studies suggest that determination of molecular changes like MSI in patients with atypical EH could help to identify early carcinogenesis and synchronous endometrial carcinoma [49, 50]. Experts recommend annual hysteroscopy and endometrial sampling in women with Lynch Syndrome beginning at age 35 [51]. This recommendation is supported by data from a prospective observational cohort study including 41 women with HNPCC comparing the accuracy of office hysteroscopy and endometrial sampling with transvaginal ultrasound alone. While both diagnostic methods had a similar specificity, the positive likelihood ratio was higher and the negative likelihood ratio lower in office hysteroscopy and endometrial sampling compared to transvaginal ultrasound [52]. However, larger studies are needed to confirm these findings.
Management of EH
A number of different aspects should be considered in the treatment of EH. Depending on the histological features and the patient´s medical history, all established risk factors for progression to EC or the concurrent presence of the disease should be determined. In addition, a specialized gyneco-pathologist should be consulted given the diagnostic uncertainties of differentiating between EH, atypical EH, and EC. The 2014 WHO classification of EH for the two—EH without atypia (benign EH) and atypical EH—should be applied in order to guarantee comparability of histopathological data both in clinical practice and in academic studies. The presence or absence of nuclear atypia is the most important factor for appropriate therapy planning and monitoring. EH is mostly associated with excessive exposure to unopposed estrogen. It is therefore crucial to supplement any form of treatment by removing the source of excessive estrogen, for example, by encouraging obese patients to lose weight, stopping any type of unopposed estrogen therapy, treating anovulation (e.g., in PCOS patients or patients with hyperprolactinemia), or identifying and removing estrogen-secreting tumors. Additionally, it is important to consider the necessity of contraception and fertility issues in premenopausal EH patients, depending on their family planning status. The most important treatment options for EH can be divided into three subgroups:
1.
Surveillance (watchful waiting)
2.
Surgical treatment (hysterectomy ± bilateral salpingo-oophorectomy)
3.
Progestin therapy
Surveillance
Surveillance alone might be an option for patients with benign EH (EH without atypia) and desire to preserve fertility when progestin therapy is not an option. In these cases it is especially important to eliminate potential sources of excess estrogen. Follow-up endometrial sampling should be conducted to exclude progression to atypical EH or EC given the 5% risk of progression over 20 years [4].
Anzeige
Surgical treatment
The risk of disease progression or simultaneous EC is high for atypical EH. Thus, hysterectomy should be recommended to most patients with atypical EH, especially to all postmenopausal patients and to premenopausal women who have completed their families. If surgery is not an option or if the patient wishes to preserve her fertility, progestin treatment with close follow-up might be considered as an alternative [2]. Total hysterectomy is the curative treatment of choice in patients with atypical EH eligible for surgery [53]. A supracervical approach should not be recommended as the cervix might be affected by precancerous lesions. Intraoperatively, the uterine specimen can be assessed for malignant disease by gross inspection and/or frozen section. However, the sensitivity of frozen section as a method for detecting EC during surgery is low at rates of only 73%–88% [54‐56]. Of note, one study even reported a sensitivity of only 27% [57]. In addition, bilateral salpingo-oophorectomy should be considered in women with early EC given the high prevalence of ovarian cancer among young women with EC. For example, in a systematic literature review, 2904 cases of women with simultaneous EC and ovarian cancer (SEOC) were identified with 1035 (36%) of them being premenopausal or < 50 years of age [96]. The proportion of women with SEOC among all reported EC cases was 842/23,498 (3%). Microsatellite instability with mutations in mismatch repair genes compatible with HNPCC were identified in 40% of women analyzed. Thus, young women with EC have a high risk of synchronous ovarian cancer. In young women with EC, bilateral salpingo-oophorectomy or careful histological assessment of both ovaries is recommended in order to confirm or rule out SEOC [58]. HNPCC testing should be offered to all young women with EC. The option of bilateral salpingo-oophorectomy should be discussed individually with every patient taking into account potential risks of the additional procedure as well as long-term adverse effects and the risk of ovarian cancer.
Progestin therapy
Multiple studies support the efficacy of progestins in treating both benign and atypical EH [59‐64]. Progestin therapy is therefore the most widely used approach for treating women with EH. The progestin supply activates progesterone receptors, which leads to decidualization of the endometrial stroma and subsequently to endometrial thinning [2]. Especially in premenopausal women with benign EH and a desire to preserve fertility, progestin administration should be the therapy of first choice. When a high risk of concurrent EC is suspected, initial endometrial biopsy should be supplemented with a dilation and curettage procedure to exclude any malignancy. Progestin therapy is contraindicated in patients with thrombophilia, hormone receptor-positive breast cancer, liver failure, known allergy to progestins and during pregnancy.
Different types of progestins and different routes of administration have been proven to be effective in treating EH. While orally administered megestrol acetate and medroxyprogesterone acetate (MPA) were formerly the most widely used therapeutics, the levonorgestrel-releasing intrauterine device (LNG-IUD), which releases 20 μg of LNG over 24 h (LNG 52/5) for a period of 4 to 5 years, has replaced oral progestin therapies as current first-line therapy in many countries. Indeed, in patients with benign EH, regression to healthy endometrium has been reported in up to 90% upon treatment with the LNG 52/5 IUD [65, 66]. In women with atypical EH and/or early EC, treatment with the LNG 52/5 IUD has been shown to lead to complete regression in approximately 75–85% of patients [2]. Randomized trials reported that the LNG 52/5 IUD is more effective than orally administered progestins in the treatment of EH, while having fewer systemic side effects and providing effective contraception [67‐69]. Through its local effect on the endometrium, the LNG 52/5 IUD evades absorption and metabolism by the intestinal flora and the liver, where progestin is associated with sedative effects [70, 71]. Other side effects of orally administered progestins include bloating, nausea, headaches, and mood swings or even depression. Irregular vaginal bleeding patterns, including spotting, represent another typical side effect of progestin treatment. This is true for both oral and intrauterine treatments. A meta-analysis of 34 observational studies found no difference in vaginal bleeding irregularities in women treated with oral progestins as compared with women who received the LNG 52/5 IUD [72].
Although potentially more effective, the LNG 52/5 IUD might not constitute an appropriate therapeutic approach for all patients with EH. Oral progestins might be a better option for women who are eager to have children, patients with IUD-related dysmenorrhea, or anatomic factors complicating IUD placement. When treating EH with oral progestins, patients should receive a continuous therapeutic dose over three to six months. Therapeutics include progestin monotherapies and combined estrogen-progestin drugs (oral contraceptives). As previously mentioned, the most common oral progestin monotherapeutics are megestrol acetate and MPA [64, 65]. The doses of MPA used in the literature depend on the type of EH and vary from 10 mg per day for benign EH to 600 mg per day in EIN [73]. Overall, in order to treat EIN progestin therapy should be administered continuously and in higher doses than for treatment of benign EH [66, 74‐76]. Moreover, cyclic progestin therapies are more frequently associated with vaginal bleeding irregularities than continuous dosing.
Anzeige
However, these medications do not provide contraception. As progestin medications are contraindicated during pregnancy, additional birth control should be advised to premenopausal women using these therapies. To date, no high-quality data supporting the use of oral contraceptives in the treatment of EH are available, although the effect of progesterone dominates at the tissue site in combined estrogen-progestin drugs [77].
The therapeutic success of progestin therapy should be monitored by endometrial sampling on a 3-monthly or 6-monthly basis. Especially in women with atypical EH a thorough follow-up is mandatory. If regression to a healthy endometrium can be demonstrated histologically, premenopausal patients who would like to preserve fertility may end progestin therapy after 3 to 6 months and try to become pregnant. In fact, after successfully completing progestin therapy, some women with EH are able to conceive. A meta-analysis including 28 studies with a total of 1038 patients with atypical EH or early EC reported that 34% of patients conceived after progestin treatment (95% CI, 30–38%) and 20% of these women actually delivered a baby [73].
In postmenopausal women or premenopausal women without an immediate desire to become pregnant, progestin therapy should be continued as maintenance therapy with further follow-up via endometrial sampling, especially if vaginal bleeding abnormalities recur [78, 79]. If atypical EH persists or if EC develops despite continued progestin therapy, hysterectomy is recommended.
Systematic literature search “efficacy of progestin treatment in women with EH”
We performed a literature search of the databases PubMed and Cochrane Controlled Trials register (search date 30–06-2020) using the search terms: ((((("progestinic"[All Fields] OR "progestinics"[All Fields]) OR "progestins"[Pharmacological Action]) OR "progestins"[MeSH Terms]) OR "progestins"[All Fields]) OR "progestin"[All Fields]) AND (("endometrial hyperplasia"[MeSH Terms] OR ("endometrial"[All Fields] AND "hyperplasia"[All Fields])) OR "endometrial hyperplasia"[All Fields]) AND (((((("therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "therapy"[MeSH Subheading]) OR "therapy"[All Fields]) OR "treatment"[All Fields]) OR "treatment s"[All Fields]). This search yielded 749 citations. We then restricted the search to the last 20 years (January 2000 to June 2020) resulting in 385 citations. The abstracts of these publications were screened and 33 of them were selected that included original data from retrospective or prospective comparisons of endocrine treatment options with progestins compared to placebo or no treatment. These studies were retrieved in full and a reference search was performed, yielding an additional 3 citations. In summary, we identified 7 systematic reviews and/or meta-analyses [65, 66, 72, 73, 80‐82], 21 cohort studies [59, 61, 74‐76, 78, 79, 83‐96], 1 case–control study [60], 6 randomized controlled trials [97‐102], and one case report [103]. Table 1 shows the study characteristics and results of the 6 randomized clinical trials with patient-specific data analyzing the efficacy of progestin treatment in women with EH. Table 2 shows the study characteristics and results of the 21 cohort studies with patient-specific data analyzing the efficacy of progestin treatment in women with EH.
Table 1
Patient characteristics and results of randomized controlled trials analyzing the efficacy of progestin treatment in women with EH
Author | Year | Study type | Number of patients | Population characteristics | Intervention | Regression of EH | Persistence/pro-gression of EH | Side effects |
|---|---|---|---|---|---|---|---|---|
Dolapcioglu [97] | 2013 | RCT | 104 | simple EH (n = 61), atypical EH (n = 43) | Oral MPA (10 mg/day; n = 52) vs. LNG-IUD (n = 52) both for 3–6 months; 2-year follow-up | 64% (MPA) vs. 100% (LNG-IUD) after 6 months | 22/51 (43%) for MPA vs. 4/51 (8%) for LNG-IUD after 2 years; 50% (MPA) vs. 84% (LNG-IUD) after 3 months | – |
Orbo [98] | 2008 | RCT | 258 | EH without further differentiation | LNG-IUD vs. oral progestin, observation for 6 months; follow-up for 24 months | LNG-IUD more effective vs. oral progestins and observation after 6 months (p = 0.001) and after follow-up | No case of EC during follow-up (56 to 108 months) | – |
Ismail [99] | 2013 | RCT | 90 | EH without atypia | Cyclical MPA 10 mg/day vs. cyclical NETA 15 mg/day vs. LNG-IUD for 6 months | 36.6% vs. 40% vs. 66.7% | No case of EC | – |
Karimi-Zarchi [100] | 2013 | RCT | 40 | EH without atypia | Cyclical MPA 20 mg/day vs. LNG-IUD for 3 months | LNG-IUD more effective (p < 0.05) | – | Better satisfaction; less side effects with LNG-IUD |
El-Behery [101] | 2015 | RCT | 138 | EH without further differentiation; diagnosed by ultrasound | Oral dydrogesterone vs. LNG-IUD for 6 months | LNG-IUD more effective (96% vs. 80%) | Recurrence rate lower with LNG-IUD (0% vs. 12%) | Patient satisfaction better with LNG-IUD despite more spotting |
2016 | RCT | 153 | EH without further differentiation | LNG-IUD vs. oral progestin vs. observation for 6 months; follow-up for 24 months | – | Histological recurrence in 55/135 (41%) with CR; Recurrence rates similar in three therapy groups; recurrence dependent on menopausal status (p = 0.0005) and estrogen level (p = 0.0007) | – | |
Pooled analysis | – | RCT (n = 6 including one Update) | 783 | – | – | LNG-IUD with higher rates vs. oral progestins in all studies | LNG-IUD with lower rates of persistence/recurrence in 2 studies | Less side effects with LNG-IUD in 1 study; better patient satisfaction in 2 studies |
Table 2
Patient characteristics and results of prospective and retrospective cohort studies analyzing the efficacy of progestin treatment in women with EH
Author | Year | Study type | Number of patients | Population characteristics | Intervention | Regression of EH | Persistence/progression of EH | Side effects |
|---|---|---|---|---|---|---|---|---|
Reed [59] | 2009 | CS | 185 | Complex (n = 115) or atypical EH (n = 70) on independent pathology review | Progestin therapy (oral MPA or MGA or NETA) or no therapy | Complex EH: 59% (68/115) with progestins vs. 12% (14/115) with no therapy; Atypical EH: 54% (38/70) with progestins vs. 8% (6/70) with no therapy | 28.4% with progestins vs. 30% with no therapy (complex EH); 26.9% with progestins vs. 66.7% with no therapy (atypical EH); EC G1 in 11/28 follow-up hysterectomies | – |
Dhar [61] | 2005 | CS | 4 | Endometrioid EC, G1, PR positive | LNG-releasing IUD for at least 6 months | 1/4 | 3/4 | IUD expulsion (n = 3); emergency curettage (n = 1) |
Wildemeersch [83] | 2003 | CS | 12 | Simple EH (n = 7), EH with atypia (n = 5) | LNG-releasing IUD (14 µg/d) for at least 12 months | 12/12 | One patient developed EC, G1, which regressed in consecutive biopsies | – |
Mandel-Baum [84] | 2020 | CS | 245 | Atypical hyperplasia on in-house pathology report | Oral progestin therapy (n = 140 MGA; n = 28 MPA; n = 8 others) or LNG-IUD (n = 69) for at least 1 month | 78.7% (LNG-IUD) vs. 46.7% (systemic progestins) | Progression to EC: 4.5% (LNG-IUD) vs. 15.7% (systemic progestins) | Morbidly obese women had higher benefit from LNG-IUD (HR 4.72; 95% CI 2.83–7.89) for CR) |
Marra [75] | 2014 | CS | 132 | EH without atypia (simple or complex) | Oral progesterone in 2nd half of menstrual cycle for 18 months or no treatment | 95% vs. 75%, p = 0.05, for simple EH; 89% vs. 35%, p < 0.001, for complex EH | Regression rates were dose-dependent: 82%, 98%, and 100% for 100 mg, 200 mg and 300 mg | – |
Simpson [76] | 2014 | CS | 44 | Atypical EH (n = 19), EC G1 (n = 25) | Oral progestin therapy (n = 140 MGA; n = 28 MPA; n= 8 others) or LNG-IUD (n = 69) for at least 1 month | 24/44 (55%) | 20/44 (45%); 13/44 with regression later recurred; 3/44 were up-staged | – |
Park [79] | 2013 | CS | 48 | EC G1 with superficial myometrial invasion or EG G2/3 with no myometrial invasion | Oral progestin therapy (n = 14 MGA; n = 34 MPA) for a median of 6 months | 37/48 (77%) | 16/37 (43%) | Median time to CR 17 weeks; No mortality; 10 live births |
Park [78] | 2013 | CS | 33 | Recurrence after progestin treatment for EC G1: atypical EH (n = 13), EC G1 (n = 20) | Oral progestin therapy (n = 3 MGA; MPA; n = 30) for a median of 6 months | 28/33 (85%) | 5/33 (15%) | No mortality |
2007 | CS | 20 | Simple EH (n = 12), EH with atypia (n = 8) | LNG-releasing IUD (20 µg/d) for at 14–90 months | 11/12 | 1/12 had persisting benign EH | – | |
Yang [86] | 2019 | CS | 160 | atypical EH (n = 120), EC stage I without myometrial invasion (n = 40) | Hysteroscopic resection + oral progestin therapy until CR | 148/160 (93%) | 4/160 (2%) | 15 of 60 attempting pregnancy became pregnant |
Pal [74] | 2018 | CS | 32 | atypical EH (n = 17), EC G1/2, stage I (n = 15) | LNG-IUD for 6 months | 80% (atypical EH) vs. 67% (EC G1) vs. 75% (EC G2) | 3/32 | 1/5 became pregnant and delivered |
Scarselli [87] | 2010 | CS | 34 | EH without atypia (n = 30), atypical EH (n = 4) | LNG-IUD (20 µg/day) for 5 years (range 12–60 months) | 32/34 | 2/32 persistence; after mean follow-up of 17 years 9 had hysterectomy with EH in 5/9 cases | |
Buttini [88] | 2009 | CS | 57 | EH without atypia (n = 41), EH with atypia (n = 16) | LNG-IUD (n = 26), oral progestin (n = 10), hysterectomy (n = 21) | 21/26 (LNG-IUD) vs. 9/10 (progestin) | 2/32 persistence; 0/57 developed EC | 1 LNG-IUD removed for side effects |
Varma [89] | 2008 | CS | 105 | EH without atypia (n = 96), EH with atypia (n = 9) | LNG-IUD for 2 years | 96% (90/94) after 1 year; 90% (94/105) after 2 years; 88/96 (92%) for EH without atypia and 6/9 (67%) for EH with atypia | 1 case of EC | – |
Gallos [90] | 2013 | CS | 344 | Complex EH without atypia or EH with atypia | Oral progestins (n = 94) or LNG-IUD (n = 250) | 95% (237/250) for LNG-IUD vs. 84% (79/94) for oral progestins (OR 3.04; 95% CI 1.4–6.8) | 8 cases of EC | Hysterectomy rates were 55/250 (22%) for LNG-IUD vs. 35/94 (37%) for oral progestins |
2013 | CS | 219 | Complex EH without atypia or EH with atypia who achieved CR after progestin treatment | Oral progestins or LNG-IUD | – | 21/153 (14%) for LNG-IUD vs. 20/66 (30%) for oral progestin; 2 cases of EC | Hysterectomy rates lower for LNG-IUD (20% vs. 32%) | |
Cholakian [92] | 2016 | CS | 60 | EH with atypia (n = 25); EC G1 (n = 35) | MGA (n = 42); MPA (n = 11); LNG-IUD (n = 22); multiple regimens possible | – | – | Median weight change greater for MGA vs. LNG-IUD (+ 2.9 vs. + 0.05 kg); BMI < 35 gained more weight vs. BMI ≥ 35 (+ 2.3 vs. − 0.7 kg/month); for BMI ≥ 35, MGA had more weight gain than LNG-IUD (+ 2.2 vs. − 5.4 kg) |
Kim [93] | 2016 | CS | 75 | EH without atypia (n = 60); EH with atypia (n = 15) | LNG-IUD for 12 months | 95% (36/38) after 12 months | 1 case with residual EH | – |
Marnach [94] | 2017 | CS | 94 | Endometrial intraepithelial neoplasia | LNG-IUD | 87% (no atypia); 62% (with atypia); 22% (adenocarcinoma) | – | – |
Haoula [95] | 2011 | CS | 51 | EH without atypia (n = 32); EH with atypia (n = 19) | LNG-IUD for 12 months | 97% (31/32) for EH without atypia after 24 months; 84% (16/19) for atypical EH | 2 cases of persistence | – |
Kim [96] | 2013 | CS | 16 | EC G1, < 2 cm | LNG-IUD + oral MPA (500 mg/day) for 3 months | 88% (14/16); median time to CR 9.8 months | No case of progression | No treatment-related complications |
Pooled analysis | - | CS (n = 21 including two Updates) | 1087 | – | – | LNG-IUD with higher rates vs. oral progestins in 7 studies | Progression to EC lower with LNG-IUD in 2 studies; regression rates dose-dependent with oral progestins in 1 study | Hysterectomy rates lower for LNG-IUD in 2 studies; more weight gain for MPA/MGA than LNG-IUD in 1 study |
EH, endometrial hyperplasia; CS, cohort study; MPA, medroxyprogesterone acetate; MGA, megestrol acetate; NETA, norethisterone acetate; EC, endometrial cancer; G1, grading 1; LNG, levonorgestrel; IUD, intrauterine device; PR, progesterone receptor; RCT, randomized controlled trial; BMI, body mass index; CR, complete response.
EH, endometrial hyperplasia; CS, cohort study; MPA, medroxyprogesterone acetate; MGA, megestrol acetate; NETA, norethisterone acetate; EC, endometrial cancer; G1, grading 1; LNG, levonorgestrel; IUD, intrauterine device; PR, progesterone receptor; RCT, randomized controlled trial; BMI, body mass index; CR, complete response.
In addition to the RCTs and CS listed in Tables 1 and 2, we identified 1 case–control study [60] and 1 case report [103]. In the case–control study, Montz et al. assessed the feasibility of using a. LNG-IUD to treat presumed FIGO stage IA, grade 1 EC in women at high risk for perioperative complications, i.e. American Society of Anesthesiologists class III or IV. Twelve patients have been followed up to 36 months; results of biopsies were negative in 7 of 11 at 6 months and 6 of 8 at 12 months. No IUD-related complications, except for expulsion, occurred. Sixteen complications (one fatal) occurred in 9 of the 15 control patients who underwent surgery. The authors conclude that LNG-IUD is a feasible treatment with special relevance for patients with early EC and a high risk of surgical complications. In the case report, Kresowik et al. report a patient with atypical endometrial hyperplasia who developed an adenocarcinoma of the endometrium after 6 months of treatment with a LNG-IUD. The authors advocate caution when using this therapy and recommend rigorous and in-depth shared decision making.
Systematic reviews of progestin treatment for EH or early EC
In a systematic review and meta-analysis of 7 randomized trials with 766 patients, Abu Hashim et al. found that the LNG-IUD achieved a higher regression rate than oral progestins after 3, 6, 12, and 24 months (OR, 7.46; 95% CI, 2.55–21.78). Subgroup analysis showed that the effect of treatment with the LNG-IUD was superior for both simple and complex EH [65]. In another systematic review and meta-analysis including 24 observational studies and 1001 patients, Gallos et al. confirmed the superiority of the LNG-IUD to oral progestins both for complex EH (pooled regression rate, 66% vs 92%; p < 0.01) and atypical EH (pooled regression rate, 69% vs 90%; p = 0.03) [66]. In a second meta-analysis of 34 observational studies, Gallos et al. investigated the efficacy of conservative treatment in women with early EC (408 patients) or atypical EH (151 patients) [72]. Endocrine treatment achieved a pooled regression rate of 76%, a relapse rate of 41%, and a live birth rate of 28%. Twenty women were diagnosed with ovarian cancer (concurrent or metastatic) during follow-up (4%) and 10 progressed to higher than stage I EC (2%), among whom 2 women died. These data show that endocrine treatment of early stage EC is feasible, but is associated with a significant morbidity and mortality, which can be estimated at around 1 in 200. Wei et al. found a similar efficacy of progestins in women with EC G1 or atypical EH summarizing 28 studies with 1038 patients [73]. Specifically, women with EC G1 or atypical EH had a pooled rate of complete regression (CR) of 71%. Although 34% of women became pregnant, only 20% of them delivered live newborns. The CR rate for women using progestin plus IUD was higher than for IUD alone (87% versus 76%).
A Cochrane meta-analysis compared oral and intrauterine progestins for atypical EH and included only one randomized trial in which a levonorgestrel-releasing intrauterine device (LNG-IUD) was found to be superior to oral medroxyprogesterone acetate (MPA) [82]. In a more recent systematic review and meta-analysis, this finding was confirmed by Yuk et al. [75]. That meta-analysis included five RCTs with 377 patients. Here, the regression rate in women using the LNG-IUD was higher than for oral MPA among lean women (relative risk [RR] 1.41; 95% CI 1.23–1.62), whereas the two regression rates, for LNG-IUD and oral MPA, were similar among obese women (RR 1.03; 95% CI 0.94–1.13). The LNG-IUD treatment was also superior in nonatypical EH (RR 1.36; 95% CI 1.07–1.73) and mixed EH (atypical and non-atypical) (RR 1.44; 95% CI 1.21–1.71).
There is weak evidence from a meta-analysis of two RCTs with 59 patients that metformin may be equally as effective as megestrol acetate (MGA) for the treatment of EH [76].
Conclusion
In summary, the available data from individual studies (Table 1) and meta-analyses clearly show that progestins are a safe and very effective treatment in patients with EH without atypia. In these patients, oral progestins achieve regression rates of around 85% and the LNG-IUD achieves regression rates of up to 100%. In contrast, the efficacy of progestins is significantly lower in patients with atypical EH or EC G1. In these patients, regression rates between 70 and 85% may be expected and recurrence rates are high at to 40%. Treatment with the LNG-IUD seems to be more effective than oral progestins in patients with atypical EH or EC G1. The rates of live births after treatment are low at around 20%. Obese women gain more benefit from progestin treatment due to the higher relative background risk, but the treatment efficacy of progestins is higher in lean women. Additionally and notably, endocrine treatment of atypical EH or EC G1 carries a clinically relevant risk of mortality, which can be estimated as 1 in 200. Therefore, patients with atypical EH or EC G1 attempting treatment with progestins should be made aware of the low live-birth rates, the high recurrence risk, and the mortality associated with this kind of treatment. The standard of care for patients with atypical EH or EC G1 remains total hysterectomy.
Anzeige
Declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Availability of data and materials
Not applicable.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
